Irsko - angličtina - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - cefotaxime sodium - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; cefotaxime

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

wockhardt uk limited - cefotaxime sodium - powder for solution for injection/infusion - 2 gram(s) - third-generation cephalosporins; cefotaxime

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - ceftazidime pentahydrate, quantity: 1.164 g - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime viatris is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not to ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other pseudomonal antibiotics cannot be used.. indications include:. severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, eg, infected burns.. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis.. severe ear, nose and throat infections: for example, otitis media, mastoiditis.. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones.. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis.. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis.. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - cefotaxime sodium - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; cefotaxime

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

pinewood laboratories ltd - cefotaxime sodium - powder for solution for injection/infusion - 500 milligram(s) - third-generation cephalosporins; cefotaxime

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

stravencon ltd - cefuroxime sodium - powder for solution for injection/infusion - 1500 milligram(s) - second-generation cephalosporins; cefuroxime

Irsko - angličtina - HPRA (Health Products Regulatory Authority)

netpharmalab consulting services s. l. - cefotaxime - powder for solution for injection/infusion - 1 gram(s) - third-generation cephalosporins; cefotaxime

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 2.328 g (equivalent: ceftazidime, qty 2 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Austrálie - angličtina - Department of Health (Therapeutic Goods Administration)

juno pharmaceuticals pty ltd - ceftazidime pentahydrate, quantity: 1.164 g (equivalent: ceftazidime, qty 1 g) - injection, powder for - excipient ingredients: sodium carbonate - ceftazidime juno is indicated for the treatment of single and mixed infections caused by susceptible aerobic organisms with suspected or documented resistance to other antimicrobials, but not ceftazidime, and as an alternative to aminoglycosides in pseudomonal infection in patients in whom aminoglycoside toxicity is a cause for concern and other antibiotics cannot be used. indications include: severe infections in general: for example septicaemia, including neonatal sepsis, bacteraemia, and in patients in intensive care units with specific problems, e.g., infected burns. respiratory tract infections: for example, pneumonia, broncho-pneumonia, infected pleurisy, infected bronchiectasis and bronchitis. severe ear, nose and throat infections: for example: otitis media, mastoiditis. urinary tract infections: for example, acute and chronic pyelonephritis, pyelitis, cystitis, urethritis (bacterial only), and infections associated with bladder and renal stones. skin and soft tissue infections: for example, erysipelas, abscesses, cellulitis, infected burns and wounds, mastitis. gastrointestinal and abdominal infections: for example, intra-abdominal abscesses, enterocolitis. bone and joint infections: for example, osteitis, osteomyelitis, septic arthritis, infected bursitis.

Velká Británie - angličtina - MHRA (Medicines & Healthcare Products Regulatory Agency)

glaxosmithkline uk ltd - ceftazidime pentahydrate - powder for solution for injection - 250mg